阿拉伯国家药物警戒外包实践现状
该观察性研究于2020年4月1日至7月31日开展并于2026年7月复核,检索22个阿拉伯联盟成员国的监管机构网站与药物警戒指南,发现13国有药物警戒指南、其中8国指南含外包章节,各国要求差异显著,作者据此提出良好药物警戒外包实践框架草案。
要点
- 22个阿拉伯国家中仅13国有药物警戒指南,其中8国指南包含外包相关章节。
- 各国指南中外包要求的覆盖范围和详细程度差异显著,缺乏统一标准。
- 作者提出结构化良好药物警戒外包实践框架,供监管机构与上市许可持有人参考。
核心结论
- 阿拉伯国家药物警戒外包要求在国家监管法规间存在显著差异,支持需要更协调的区域性方法。
- 作者基于识别的差距和现有良好药物警戒外包实践原则,提出结构化框架草案。
研究设计与样本
- 观察性研究,实施期为2020年4月1日至2020年7月31日,并于2026年7月复核以检索最新药物警戒立法。
- 研究对象为22个被视为阿拉伯联盟成员国的国家,信息来源为监管机构网站上的药物警戒指南。
- 审阅文件包括阿拉伯良好药物警戒实践(GVP)指南第2版及埃及、沙特阿拉伯、阿联酋、阿尔及利亚、突尼斯、伊拉克、黎巴嫩、阿曼、苏丹和摩洛哥等有独立指南国家的指南。
- 设计了针对阿拉伯卫生当局现行药物警戒外包指南的问题清单。
主要发现
- 22个阿拉伯国家中,13国有药物警戒指南;这13国中8国的药物警戒指南包含外包章节。
- 阿拉伯联盟指南、埃及良好药物警戒实践指南和沙特食品药物管理局良好药物警戒实践指南包含七个模块并提及外包章节。
- 伊拉克和突尼斯等其他阿拉伯指南仅包含一个模块并提及外包章节。
临床怎么用
- 上市许可持有人、药物警戒服务提供者和监管机构可参考所提框架建立合规有效的外包安排。
- 该框架可作为未来监管协调的基础,但需进一步利益相关方咨询与验证以评估其在阿拉伯地区不同国家药物警戒体系中的适用性和可行性。
局限性
- 所提框架尚需进一步利益相关方咨询和验证,以评估其在不同国家药物警戒体系中的适用性与可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outsourcing in pharmacovigilance has grown in the last decade. However, standards and references are lacking in this area, both for initiating and maintaining a long-term outsource relationship. There are differences in the progression of pharmacovigilance systems by regulatory agencies in these countries because only some can meet the requirements for conducting pharmacovigilance activities. This research aimed to provide an overview of the current pharmacovigilance outsourcing regulations in Arab countries, as well as recommending a draft guideline for good PV outsourcing practices that can be used as a starting point for the preparation of a pharmacovigilance outsourcing process standard. METHODS: The study was an observational study conducted during the period from 1 April 2020 to 31 July 2020, and was rechecked in July 2026 to search for the latest pharmacovigilance legislation on 22 countries that are considered members of Arab League. Regulatory authorities' websites were used as sources of information regarding the pharmacovigilance guidelines. Several documents were reviewed, including the Arab guideline on Good Pharmacovigilance Practices (GVP) version 2, guidelines for countries that have their discrete guidelines (e.g., Egypt, Saudi Arabia, United Arab Emirates (UAE), Algeria, Tunisia, Iraq, Lebanon, Oman, Sudan and Morocco). Additionally, a list of questions was designed for Arab health authorities regarding their current guidelines about pharmacovigilance outsourcing. RESULTS: Of the 22 Arab countries, 13 countries have pharmacovigilance guidelines; 8 of these 13 countries have pharmacovigilance guidelines with outsourcing sections. The Arab League guideline, Guidelines of Good Pharmacovigilance Practices in Egypt, and Saudi Food and Drug Authority Guideline on Good Pharmacovigilance Practices contain seven modules with outsourcing sections mentioned, while other Arab guidelines for Iraq and Tunisia contain only one module with outsourcing section mentioned. CONCLUSIONS: This study identified substantial variability in the extent and level of detail of pharmacovigilance outsourcing requirements across the national pharmacovigilance regulations of Arab countries, supporting the need for a more harmonized regional approach. Based on the identified gaps and existing principles of good pharmacovigilance outsourcing practice, the authors propose a structured framework for Good Pharmacovigilance Outsourcing Practice that may serve as a foundation for future regulatory harmonization and support marketing authorization holders, pharmacovigilance service providers, and regulatory authorities in establishing compliant and effective outsourcing arrangements. Further stakeholder consultation and validation are warranted to assess the applicability and feasibility of the proposed framework across different national pharmacovigilance systems in the Arab region.
引用
- Abdeldayem I, Alshammari TM, Palin K, et al. Current Pharmacovigilance Outsourcing Practices in Arab Countries. Drug Saf. 2026. PMID: 42875658. doi:10.1007/s40264-026-01734-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。